Board of Managers

Mr. Powers has spent the past 20 years in pharmaceutical services businesses. He spent 18 years in executive management at PRA International, a global clinical research organization serving pharmaceutical, biotechnology and medical device companies. He oversaw PRA's growth from a niche data management services provider to a full service clinical trials management organization, and expanded its operations and customer base from US-centric to international. Mr. Powers launched PRA's oncology therapeutic focus, a market in which PRA continues to be a leader, and he was instrumental in strategic planning and eight acquisitions. During his tenure, the company grew from less than $1 million to more than $450 million in annual sales and a global work force of more than 3,000 employees. He is a member of several boards in the pharmaceutical services sector and advises seed venture capital funds. Before joining PRA, Mr. Powers was responsible for identifying and managing medical technology startup businesses for University Technology Corporation. Mr. Powers received a B.S. in Administration and Management Science from Carnegie-Mellon University.

Dr. Campbell has been an entrepreneur and an economic consultant throughout his 40-year business career. He began in 1968 with an aviation consulting firm in New York and was promoted to Vice President in charge of the firm's Washington office. In 1977, he was co-founder of Midway Airlines, Inc., the first new scheduled start-up carrier after airline deregulation. At Midway, he served as Chief Financial Officer and participated heavily in raising $5.7 million of venture capital to fund Midway's start-up. He returned to the aviation consulting business in 1983 and has been founder and co-founder of two specialized consulting firms. He recently retired from his position as chairman of The Campbell-Hill Aviation Group, headquartered in Alexandria, Virginia. Throughout his consulting career he has assisted numerous start-up companies with business plan preparation, financial forecasting, detailed market analyses, and strategic planning studies. Currently he serves as Vice Chairman and acting Chief Financial Officer of Dynamic Literacy, LLC; Chairman and member of the advisory board of Targeson, LLC, a UVa-based biotechnology company; acting CFO and investor in BioMotion Analytics, LLC; and is a member of the advisory board of UVa's Heart and Vascular Center. He earned a Bachelor of Commerce degree from McGill University, an MBA from the University of Western Ontario, and a Ph.D. in business administration from Columbia University.

Mr. Thompson is of counsel to the law firm of Woods Rogers, PLC, and specializes in corporate law representing companies in diverse fields including biotechnology, information technology, and oil and gas exploration. Mr. Thompson is Secretary of Insmed Incorporated, a publicly traded biotechnology company, and a member of the Boards of Mestena Inc., an oil and gas exploration company, and Foundation Energy Management, LLC, which acquires oil and gas producing properties. He is a member of the investment advisory board of Tall Oaks Capital, L.P., a venture capital fund based in Charlottesville and has represented many biotechnology companies in the Charlottesville area including Indoor Biotechnologies, Inc., Plurogen Therapeutics, Inc., CardioConcepts, Inc., Targeson, LLC, and Phthisis Diagnostics, LLC. He is a member of the advisory board for UVa's Heart and Vascular Center and General Counsel to, and immediate past Chair of, the Board of the University of Virginia's Curry School of Education Foundation. Mr. Thompson graduated from Yale College in 1969 and UVa Law School in 1972.

Dr. Blackman is co-founder of HemoShear and co-inventor of the HemoShear technology. He is a tenured associate professor in the Department of Biomedical Engineering at the University of Virginia. Since August of 2002, Dr. Blackman has led a National Institute of Health (NIH)-funded research program investigating the role of the hemodynamic environment in regulating vascular endothelial cell biology in atherosclerosis. Prior to joining UVa, Dr. Blackman spent 3.5 years training as a postdoctoral research fellow in the Vascular Research Division of Brigham & Women's Hospital and Harvard Medical School. There he developed the first cell-culture-based model to simulate human hemodynamic flow patterns on isolated human endothelial cells, which laid the foundation for current research identifying the importance of precise hemodynamic conditions for regulating arterial vascular biology. Dr. Blackman has 19 peer-reviewed publications, served on UVa's School of Engineering and Sciences Dean's Research Advisory Committee, is a member of the Robert M. Berne Cardiovascular Research Center, is a peer reviewer for more than 12 scientific journals, and is a member of the American Heart Association Bioengineering & Biotechnology study section. Dr. Blackman obtained a B.S. in mechanical engineering from Drexel University and a Ph.D. in bioengineering from the University of Pennsylvania.

Mr. Brooks consults with life science companies that are seeking strategic advice, and access to capital to initiate, develop and grow their businesses. He is also one of Prism Ventureworks’ founding partners. Prism raised over $1.25B and has offices in Needham, MA and Venice, CA. Mr. Brooks sits on the boards of OptiScan Biomedical, Noxilizer, Confirma Inc. and Uptake Medical. He brings a wealth of strategic, clinical, operational and financial experience to his current and prospective client companies. His operational knowledge of regulatory, reimbursement, clinical adoption, marketing and distribution issues allows him to determine the optimal path businesses need to take to minimize capital requirements while driving to meaningful value inflection points and exits. Mr. Brooks was formerly a General Manager at Pfizer/Valleylab in Boulder, CO where he developed and executed a minimally invasive surgery and emerging businesses strategy. Prior to that, at Pfizer/Strato Medical, he led the growth of a rapidly evolving vascular access medical device business. Mr. Brooks has co-founded three paradigm shifting life sciences companies, Songbird Hearing, Locus Pharmaceuticals and Insulet (PODD). He is a biotechnology advisory board member for Draper Labs and the Kansas Heartland Bioventures Fund. He is a Joslin Diabetes Center Trustee, a member of M2D2, an early stage medical technology accelerator and a board member of Mass Medic’s Ignite entrepreneurial center as well as the CIMIT and MTTC advisory boards. Mr. Brooks holds an M.S. in Business and a B.B.A. cum laude from the University of Massachusetts at Amherst. He is a Certified Public Accountant and a Certified Financial Planner.

Dr. Sackier has over 25 years of healthcare experience. Trained as a surgeon in the United Kingdom, he was recruited to the United States in the 1980s and helped lead the laparoscopic surgery revolution. As a Professor at George Washington University in Washington, D.C., he founded and funded the Washington Institute of Surgical Endoscopy, a center for education, research and technological innovation. He retired from clinical practice and full time academic pursuits in 1999 but continues his associations with academia as a Visiting Professor at the University of Virginia in Medicine and Surgery and with activities in basic and clinical research supported by multiple grants. His work has led to over 120 publications, seven books and numerous chapters for 36 medical text books. Dr. Sackier has collaborated with the pharmaceutical and medical device industry and developed multiple technologies that have been licensed and brought to market with partners such as Valleylab, Pfizer, Karl Storz, Applied Medical and Pall. In the mid 1980s his team discovered and patented a line of amniotic stem cells and the resultant company, "Genethics," and licensed the rights to a publicly traded British pharmaceutical company, Proteus LLC (now Protherics, symbol: PTI). He also helped develop the AESOP robotic device and that company, Computer Motion, had a successful IPO in 1997. He has been a consultant to many healthcare companies, sits on several corporate and scientific advisory boards, advised the financial community on angel and venture funding, and assisted with due diligence on merger and acquisition and IPO activity. A frequent commentator in the media, Dr. Sackier has been a guest on radio and television to discuss a range of healthcare issues. Dr. Sackier has served the National Committee of the Steppenwolf Foundation, is a Trustee of the First Star Foundation, a member of the Virginia Hillel Board and previously Chaired the Board of the Larry King Cardiac Foundation.

Dr. Wamhoff is co-founder of HemoShear and co-inventor of the HemoShear technology. He is a tenure track assistant professor and leads an NIH-funded laboratory that studies vascular disease at the Cardiovascular Division of the University of Virginia’s Department of Medicine. Dr. Wamhoff began his fellowship at UVa to develop rodent models to investigate the molecular mechanisms of genes underlying vascular disease. During this time, he was also employed by Setagon, Inc., a Charlottesville start-up, as lead scientist to develop a novel drug-eluting stent for the treatment of blood vessel stenosis in humans. While at UVa, he has obtained more than $3.3 million funding from Pfizer, the American Heart Association, NIH, and other organizations to study the fundamental mechanisms that regulate smooth muscle cell phenotypic switching in vascular disease. Dr. Wamhoff obtained a B.S. in biology at Rhodes College and a minor in business administration, and obtained his Ph.D. from the University of Missouri where he developed swine models of diabetes and atherosclerosis. Dr. Wamhoff submitted more than 15 patents related to regulation of smooth muscle cell phenotypic switching in vascular disease, leading to licensing of the technology in 2007 to a major device company. Dr. Wamhoff has authored or coauthored 32 publications, two book chapters, and 3 commentaries. Dr. Wamhoff serves as peer reviewer for more than 10 major scientific journals and as grant reviewer for the American Heart Association. He has been the recipient of multiple awards, including the Robert M. Berne Trainee Achievement Award, the American Physiological Society Young Cardiovascular Investigator Award, the University of Virginia Department of Medicine Award for Excellence in Research and the 2008 Atherosclerosis, Thrombosis, and Vascular Biology (ATVB) Irvine Paige Young Investigator Research Award. Dr. Wamhoff devotes philanthropic time to the community by promoting health awareness as a local member of the board of directors for the American Heart Association.

Mr. Woods began his business career at General Electric in the marketing of industrial process computers. He then served as director of new aircraft development and purchasing for Eastern Airlines, concentrating on the design, purchase, and financing of the DC-9, B-737, B-727, and L-1011 fleets. He later joined Butler Aviation International to manage a corporate turnaround that became the subject of three Harvard Business School case studies. He led Butler through a major restructuring without any loss to banks or bond holders, or any dilution of the original public shareholders. The Butler companies all experienced significant growth and profitability through acquisitions in their respective industries. Butler International was listed on the NYSE and later completed a significant common stock offering through Goldman Sachs. Butler was sold to a financial buyer for cash at an attractive valuation in 1987. Mr. Woods returned to turnaround consulting, and in 1994, co-founded a merger and acquisition practice specializing in the insurance industry. He was a founding shareholder and director of the New York investment banking firm of Benedetto Gartland & Company, which specializes in raising capital for private equity funds. He currently serves as Chairman of Dynamic Literacy, LLC; Director and Chairman of the audit committee of Greenleaf Corporation, an industrial construction firm; and is a Director of Scitent, Inc. and DeHayes Consulting Group. He also serves on the executive committee of Habitat for Humanity of Greater Charlottesville, the advisory board of UVa's Heart and Vascular Center, and is co-founder of the Keswick Community Foundation. He earned B.S. and M.S. degrees in Engineering, and an MBA from Cornell University.